WO2002034912A1 - Genomes participant a l'arthrite rhumatoide, procede de diagnostic de celle-ci, procede d'evaluation de la possibilite d'apparition de celle-ci, kit de diagnostic et methode et remedes therapeutiques destines a l'ar - Google Patents
Genomes participant a l'arthrite rhumatoide, procede de diagnostic de celle-ci, procede d'evaluation de la possibilite d'apparition de celle-ci, kit de diagnostic et methode et remedes therapeutiques destines a l'ar Download PDFInfo
- Publication number
- WO2002034912A1 WO2002034912A1 PCT/JP2001/009313 JP0109313W WO0234912A1 WO 2002034912 A1 WO2002034912 A1 WO 2002034912A1 JP 0109313 W JP0109313 W JP 0109313W WO 0234912 A1 WO0234912 A1 WO 0234912A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- rheumatoid arthritis
- mutation
- onset
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- Genomes involved in rheumatoid arthritis methods for their diagnosis, methods for determining their onset, diagnostic kits for their detection, methods for treating rheumatoid arthritis, and therapeutic drugs
- the present invention relates to a genome having mutations, their transcripts, a method for diagnosing human rheumatoid arthritis using the mutations, a method for determining the possibility of developing the disease, and a diagnostic kit for detecting them. Furthermore, the present invention relates to a method for treating rheumatism and a drug for treating the same. Background art
- Rheumatoid arthritis is a systemic inflammatory disease of unknown cause that is characterized by multiple erosive arthritis, but also damages multiple organs. RA progresses chronically, with remissions and exacerbations repeated, and if left untreated, destruction and deformation of the joints, eventually leading to motor organ dysfunction. Sometimes life threatening. Therefore, RA patients suffer significant physical and mental distress over their lifetime. 'R. A has many different ways of onset, and the diagnostic criteria of the American College of Rheumatology are widely used for its diagnosis. However, the onset of RA is usually slow, ranging from weeks to months, and the presence of the rheumatoid factor as an objective indicator in the American College of Rheumatology diagnostic criteria.
- NSAID non-steroidal anti-inflammatory drug
- DMAR D disease-modifying rheumatic drug
- RA arthritis and joint destruction
- RA can only become ill if a number of causative factors including the living environment overlap. And development ⁇ A shame disease. Therefore, the proper nature of multifactor interactions must be clarified in order to correctly elucidate and properly treat diseases.
- RA is a disease with an incidence of less than 1% worldwide (N. Engl. J. Med.), Volume 322, New England Journal 'Ob' Medicin. Pp. 1277-1289, 1990), but more than about 8% develop in sibs of the patient (Cell, Vol. 85, pp. 311-318, 1996). Some genetic factors are assumed.
- knowing the likelihood of developing the disease in advance can be useful in daily life, for example, by paying attention to diet, viral infection, and stress. Onset can be delayed or prevented. Furthermore, early diagnosis and early appropriate treatment can delay the progression of RA, which is expected to improve prognosis.
- RA apoptosis is induced in vitro by anti-Fas antibody (Arthritis rheuum. Arthritis rheum., Vol. 38, No. 485-). P. 491, 1995).
- administration of an anti-Fas antibody to a transgenic mouse model of human type I T cell leukemia virus (HTLV-1) tax which is an RA model animal, suppresses edema and arthritis in the joints (Journal of Obv. NIKONORE's Investigation (J. Clin. Invest.), Vol. 98, pp.
- a disease gene for rheumatoid arthritis located within ⁇ 1 centimorgan of the DNA sequence hybridized by the microsatellite markers DX, S1001 ', DXS1047, DXS1205, DXS1227 and Z or DXS1232 on the human X chromosome.
- DR 3 disease gene of Death receptor 3
- the present invention aims to elucidate the relationship between a genomic mutation in human DR3 and the onset or the likelihood of RA, and to diagnose the onset or the likelihood of RA using the mutation with high accuracy. The challenge is to provide a method that can do this.
- the present invention provides a useful diagnostic kit for detecting a mutated genome of DR3 related to RA or a transcript mutated thereof, and further has a mutation in DR3. It provides an effective treatment method and therapeutic agent for RA patients. Disclosure of the invention
- a method for determining the onset or possibility of onset of RA using the mutated DR3 genome and its transcript in cells obtained from a subject as an indicator (in other words, a method for diagnosing RA) ) And diagnostic kits for detecting these mutations are useful, and have completed the present invention. Furthermore, the present invention is also useful as a new method for preventing, treating and treating rheumatoid arthritis.
- A, C, G and T represent each base of adenine, cytosine, guanine and thymine.
- a transcript is a product resulting from the transcription and translation of a genome, and includes, for example, mRNA, cDNA, and protein. '
- the base at position 1755 corresponds to the 564th base in the sequence (accession number NM-003790) registered in the gene bank as cDNA. Based on the base at the 3 'end of exon 5 of this genomic DNA, if the base at the end of the int after one base is the first, the deletion at positions 2443 to 2456 is This corresponds to the deletion of the bases 622 to 635 from the 3 'end.
- the mutation at position 2531 is -538th
- the mutation at position 2678 is The mutation corresponds to the -391 base
- the mutation at position 2826 corresponds to the -243 base (see Figure 1).
- T is 28 consecutive nucleotides (positions 2443 to 2470)
- the number may increase or decrease by 3 nucleotides.
- a genome and its transcripts for example, mRNA, cDNA, etc., can be used.
- mRNA can be converted to cDNA, if necessary, and used.
- genomic fragments containing one or more of these mutations Useful as a '
- transcripts such as proteins expressed from the genome.
- the transcripts of these genomes are also useful as reagents for determining the onset of RA or the likelihood of the onset, or as raw materials thereof.
- identification of a mutant genome and diagnosis of RA (that is, determination of the onset of RA or the possibility of onset thereof) can be performed, for example, as follows.
- the genome of the subject can be obtained from all cells of the human body by a conventional method. For example, it can be obtained from hair, organs, peripheral lymphocytes, synovial cells, and the like. Further, the obtained cells can be obtained by culturing and growing the cells. In addition, the obtained genomics can be analyzed by, for example, PCR Polymerase Cham Reaction), NASBA (Nucleic acid sequence based amplification), TMA (Transcription-mediated amplification), and SDA (Strand Displacement Amplification). It can be used after being amplified by a commonly used gene amplification method.
- Examples of the method for detecting a mutation in the genome include, but are not limited to, an aryl-specific oligonucleotide probe method, an oligonucleotide-oligonucleotide ligation assay, an oligonucleotide ligation assay, and the like.
- PGR-SSCP, PCR-CFLP, PCR-PHFA, Invader, RCA (Rolling Circle Amplification), Primer Oligo Base Extension (Primer Oligo Base Extension) Can be
- the nucleotide sequence at positions 21 to 4825 of SEQ ID NO: 1 can be determined, for example, by the direct sequence of a PCR product amplified from the genome by the following primer combinations (1 to 3).
- the nucleotide sequence at positions 1 to 20 of SEQ ID NO: 1 is a sequence registered in GeneBank as cDNA (session number NM-003790). '
- the mutation used in the present invention is a substitution of the base at position 1755 of SEQ ID NO: 1 from A to G, a substitution of the base at position 2531 of SEQ ID NO: 1 from C to T, the base sequence of position 2678 of SEQ ID NO: 1
- the substitution of the base at position 2826 of SEQ ID NO: 1 with the G from the sense primer at positions 1051 to 1078 of SEQ ID NO: 1 and the antisense primer at positions 4058 to 4085 of SEQ ID NO: 1 Can be detected by the direct sequence of the PCR product amplified by the primer, and the deletion of the nucleotides at positions 2443 to 2456 of SEQ ID NO: 1 can be detected.In other words, the mutation of the above five nucleotides can be detected. If they occur at the same time, they can be detected simultaneously by the above PCR product.
- substitution of nucleotides C to T at position 921 of SEQ ID NO: 1 is amplified by the sense primers at positions 21 to 38 of SEQ ID NO: 1 and the antisense primers at positions 1517 to 1535 of SEQ ID NO: 1.
- the sequence of PCR products More detectable.
- the above mutation can be detected by preparing a sense primer and an antisense primer for the region containing the mutation and direct-sequencing the PCR product amplified from the genome.
- detecting one or more of the above mutations in the genome of SEQ ID NO: 1 it is possible to make a diagnosis (determination of onset or possibility of onset) of RA in a subject with high accuracy.
- the primer used in the present invention can be prepared by a conventional method using a DNA synthesizer or the like.
- These mutations can also be detected by using an appropriate restriction enzyme and detecting a difference in the size of the genomic fragment to be cleaved by Southern blotting or the like.
- deletion of the nucleotides at positions 2443 to 2456 of SEQ ID NO: 1 can be detected by subcloning the PCR product into plasmid and sequencing it.
- Use of the c (b) transcript which can also be detected by differences in the size of the PCR product amplified by the sense primer at positions 2369 to 2389 and the antisense primer at positions 2514 to 2535 of SEQ ID NO: 1 '
- the diagnosis of RA (onset or the possibility of onset) of RA in a subject can be enhanced by detecting transcripts such as mRNA and protein that cause changes due to genomic mutation. It can be done with precision.
- a transcript when mRNA is used, a sequence containing a mutated portion, for example, positions 1534 to 3306 of SEQ ID NO: 1 are recombined into an expression vector, and transfected into cells. Ratio of derived mRNA Mutation can be detected by, for example, a method of preparing cDNA from mRNA and a method of sequencing cDNA.
- a vector having a substitution of the nucleotide at position 2678 of SEQ ID NO: 1 from A to D the vector having a mutation of the nucleotide at position 2826 of SEQ ID NO: 1 from A to G, position 2636 2792 of SEQ ID NO: 1 was retained.
- mRNA is detected. A part of the nucleotide sequence of this mRNA is SEQ ID NO: 4, and the intron insertion causes a frame shift, which results in mutation of amino acid residue and termination codon. Appear.
- the amino acid sequence of the protein expressed from this mRNA is shown in SEQ ID NO: 5.
- a vector in which position 1534 3306 of SEQ ID NO: 1 has been recombined into an expression vector or a recombinant vector in which an A to G mutation has been introduced into the portion corresponding to position 1755 of SEQ ID NO: 1 SEQ ID NO: 1 with a C to T mutation at position 2531, SEQ ID NO: 1 with an A to T mutation at position 2678, SEQ ID NO: 1 at position 2826 with an A to G mutation
- the amino acid residue at position 159 in the amino acid sequence of SEQ ID NO: 2 is mutated from Asp to Gly.
- a method for detecting the protein shown in SEQ ID NO: 5 caused by the above-described mRNA splicing abnormality, and the amino acid residue at position 159 in the amino acid sequence of SEQ ID NO: 5 is Asp
- a method for detecting a protein in which the amino acid residue at position 159 in SEQ ID NO: 2 has been mutated from Asp to Gly can be The detection of the mutant protein may be performed according to a normal protein sequencing method.For example, an antibody that recognizes only the mutant protein is prepared and detected by an ELISA method.
- Methods for detecting mutations using enzymes and the like and cutting them using a protein sequencer methods for detecting mutations in the isoelectric point of amino acids, and methods for detecting differences in mass by mass spectrometry.
- a method is provided in which an antibody that recognizes only the mutant protein is prepared and detected by ELISA.
- Apoptosis is caused, for example, in the following order.
- Death factors eg, Fas ligand, TNF, Apo3L (DR3 ligand) and TRIAL
- DR3 ligand DR3 ligand
- TRIAL binds to death receptors (Fas, TNF receptor and DR3 etc.)
- adapter proteins eg, FADD and TRADD
- caspase molecules ultimately causing apoptosis.
- caspase-8 when stimulated, caspase-8 binds via the death receptor adapter protein to become activated caspase-8, further activates downstream force-spase3 and the like, and finally causes apoptosis
- caspase 8 is known to be a variant such as caspase 8 / a and caspase 8 / b.
- the protein expressed from the genome detected by the present invention has a mutation due to a splicing abnormality, and the mutation causes the expression of a mutant form of DR3 lacking the des domain region.
- DR3 forms a trimer, and it is known that an adapter protein binds to the desdomain region of the trimer.
- This mutant receptor also forms a complex with the normal 'receptor', but this complex cannot bind the adapter protein TRADD, resulting in activation of caspase-8. And apoptosis is not induced. '. Therefore, it is considered that mutant DR3 derived from the genome having the mutation detected in the present invention has no functional function and acts on dominant negative.
- Cells used for diagnosis can be obtained from all cells of the human body by a conventional method.
- the cells to be used preferably include peripheral blood mononuclear cells.
- the obtained cells are stimulated with a reagent or the like.
- the reagent used for stimulation is not particularly limited as long as it is a reagent used for normal stimulation.
- Death receptor ligands such as Gand, TNF, DR 3 ligand, anti-Fas antibody, actinomycin D, radiation, darcocorticoid, honole ball 12—Miristate 13—Acetate (PMA ), Phytohemagglutinin (PHA) and the like, and one or more of these may be used together.
- Preferable examples include DR3 ligand, PMA, and PHA (provided that stimulation by PMA and PHA is involved in various signal transduction systems including DR3).
- R3 ligand and the like are examples of these.
- the time for adding the reagent is not particularly limited, but may be, for example, about 1 to 72 hours, preferably 12 "to 48 hours.
- the stimulated cells and control cells are lysed with, for example, a solubilization buffer or the like, and caspase 8 is detected.
- force-spase 8 can be carried out by any method commonly used for protein detection, such as, but not limited to, by, for example, 'Western blotting'.
- Western blotting includes, for example, a method in which, after electrophoresis on an SDS-polyacrylamide gel, the DNA is transferred to a PVDF membrane and detected with a labeled anti-caspase-3 antibody that binds to caspase-8.
- caspase 8 In healthy subjects, the expression level of caspase 8 in stimulated cells is lower than that in unstimulated cells, but not in RA patients.
- the measured caspase 8 concentration was compared before and after stimulation, and if the concentration did not decrease, the subject was diagnosed as RA, a patient, or was highly likely to develop RA. You can also judge. That is, by detecting other mutations affected by the genomic transcript, it is possible to diagnose that the patient is an RA patient or determine that the possibility of developing RA is high.
- RA joints synovial cells contribute to proliferation and cause joint destruction. Therefore, an anti-Fas antibody capable of inducing apoptosis in synovial cells is considered to be effective as a therapeutic agent for RA. In fact, clinical trials of anti-Fas antibodies are currently underway as therapeutic agents for RA.
- the above-mentioned mutant DR3 caused by mutation of the DR3 genome cannot induce apoptosis in cells, and this is considered to be the etiology of RA patients with a mutation in DR3.
- DR3, like Fas belongs to the death receptor family and can induce apoptosis in cells.
- the present invention provides the following methods and agents for treating RA.
- Low DR 3 agonist A method for treating rheumatoid arthritis, which comprises supplementing a molecular compound.
- ⁇ A therapeutic drug used for the treatment of patients with rheumatoid arthritis having a mutant DR3 which is a transcript of the genome according to the present invention, and which does not have the mutation.
- 'Normal DR.3 or the normal DR A drug for treating rheumatoid arthritis which is mainly composed of DNA encoding 3 or a low molecular weight compound as an agonist of DR 3.
- the method of complementing normal DR3 is not particularly limited.
- known protein expression systems and gene transfer methods can be used. Specifically, when a protein is expressed in mammalian cells, A method using an expression vector, a virus vector, or the like used for the above is mentioned.
- Apo3L as the low-molecular compound, Apo3L (carreto), which is known as DR3 ligand, is used.
- Antibiotics (Curr. Biol.), Vol. 8, pp. 525-528, 1998, and anti-DR3 antibodies that may act as ago: .
- Specific examples of the anti-DR3 antibody include immunity (Irntrmnity)
- the 79-88 pages include such as polyethylene click polyclonal antibody according to I "7 years), they can be considered a method of administering into the body, such as by oral or intravenous.
- low molecular weight compound also refers to a compound containing a protein such as a peptide.
- the normal DR3 or the DNA encoding the normal DR3 and the low molecular weight compound as an agonist of the DR3 are used only selectively as therapeutic agents. Instead, they can be used in combination. Therefore, a therapeutic method using at least one of the normal DR3 or the DNA encoding the normal DR3 and a low-molecular compound as an agonist of the DR3 is also effective.
- the kit for the diagnosis (onset or possibility of onset) of RA may be any reagent that can detect the above-mentioned genomic or transcript mutations, for example, primers, probes, antibodies, etc. It is not particularly limited, and can be obtained by further combining other reagents.
- kits for expressing a genome may include a primer designed to amplify a genomic region containing one or more of the above mutations, and further comprise a 'genome containing one or more of the above mutations'.
- One or more reagents needed to detect mutations such as probes designed to detect regions, restriction enzymes, and reagents used in sequencing methods such as the Maxam Gilbert and chain terminator methods Combined kits.
- a kit containing a fluorescently-labeled dideoxynucleotide is included. '.' ..
- kits for detecting a protein includes a kit containing an antibody that recognizes a mutant protein.
- kits for detecting mRNA include primers designed to amplify the region containing the mutation, as well as probes, restriction enzymes, and restriction enzymes designed to detect the mutation.
- Reagents used in nucleotide sequencing methods such as the Maxam-Gilbert method and the chain terminator method. Kits that combine one or more reagents required to detect mutations can be used. Also preferably, a fluorescently labeled dideoxynucleotide is used. Kits that include the password.
- the diagnosis of RA (judgment of onset or possibility of onset thereof) can be made with high accuracy.
- the diagnostic (judgment) kit of the present invention is, for example, a kit containing primers. If the primer can detect one or more mutations of the present invention, the primer is appropriately selected according to the detection method. However, preferably, a set of a sense primer at positions 2717 to 2736 of SEQ ID NO: 1 and an antisense primer at positions 3284 to 3306 of SEQ ID NO: 1 and a sense at positions 1051 to 1078 of SEQ ID NO: 1 Set of primer and antisense primer at positions 4058 to 4085 of SEQ ID NO: 1, sense primer at positions 21 to 38 of SEQ ID NO: and antisense primer at positions 1517 to 1535 of SEQ ID NO: 1 Set, more preferably, the position of SEQ ID NO: 1.Set with the sense primers 1534 to 1556 and the antisense primer at positions 3284 to 3306 of SEQ ID NO: 1, SEQ ID NO: The set includes a sense primer at positions 667 to 687 of position 1 and an antisense primer at positions 1517 to 1535 of sequence number
- FIG. 1 shows the positions of the .5 mutations.
- FIG. 2 is an electrophoresis photograph showing the electrophoresis patterns of normal and defective alleles.
- Figure 3 is an X-ray film photograph in which splicing abnormalities due to five mutations were detected by Southern blotting.
- FIG. 4 is an X-ray film photograph in which a splice abnormality caused by the mutation at position 2678 of SEQ ID NO: 1 was detected by Southern blotting.
- FIG. 5 is an X-ray film photograph of the result of immunoprecipitation with an anti-GFP antibody, followed by Western blotting with an anti-Xpress antibody.
- FIG. 6 is an X-ray film photograph of the result of immunoprecipitation with an anti-His antibody followed by Western blotting with an anti-Flag antibody.
- lOxPfu buffer 200 mM Tris-HCl (pH 7.5), ⁇ lOOmM chloride rim, lOOraM ammonium sulfate, 20 mM magnesium sulfate, 1% triton X-100, lmg / ml serum albumin N
- TAE buffer 0.04M Tris acetic acid, 0.002 Ethylenediaminetetraacetic acid
- ⁇ Buffer 500 mM Tris-HCl (pH 7.5), lOOm magnesium chloride, l QmM dithiothreitol, l OOOmM sodium chloride
- lOxPCR II buffer 500 mM potassium chloride, lOOmM Tris-HCl (pH 8.3) lOxSSC: 1.5 M sodium chloride, 0.15 M sodium citrate (pH 7.0) Buffer A: lOOmM Ris hydrochloric acid (pH9.5), 300raM sodium chloride
- FCS fetal serum
- X-gal 5—promo to 4—chloro-3—indolinyl j3—D—galactoside
- Solubilization buffer 50 mM Tris-hydrochloric acid (pH 7.5), 150 rnM sodium chloride, 1 NP 0. 0.5% sodium deoxycholate, Protea ⁇ Zeinhibitor
- TBS-T solution 20 mM Tris-hydrochloric acid (pH 7.6), 137 mM sodium chloride, 0.05% Teen20
- HRP Horseradish 'Nsperoxidase'
- Washing buffer 50raM Tris-HCl (pH7.5), 1M NaCl, 0.1% '' NP40, 0.05% sodium deoxycholate, protease inhibitor cocktail
- the genomic DNA was determined by the guanidine thiosocyanate method (Journal of the Japanese Society of Transfusion Society, Vol. 40, No. 2, pp. 413, 1994). Prepared from blood. That is, cell membrane lysate was added to 10 ml of peripheral blood sampled by EDTA, I solution: 0.32 M sucrose, 1% (v / v) Triton X-100, 5 mM magnesium chloride, 12 mM dris monohydrochloride ( ⁇ ⁇ 7.6)) We calmed 20 tnl, mixed by inversion and centrifuged at 3000 rpm for 10 minutes to collect nuclei.
- nuclei contain nuclear membrane lysate (II solution: 4M guanidine thiosinate, 12mM EDTA, 375mM sodium chloride, 0.5% N-square sodium dodecanoyl sarcosine, 0.1M j3 -. Menorekapu Toeta Nord, 12 mM Application Benefits scan hydrochloric acid (pH 7.6)) 5 ml was added, 55 ° C shall be kept for 10 minutes to prepare a O Rigeno arm DNA ethanol precipitation c
- the obtained PCR product was purified using a commercially available kit (QIAquic PCR Purification Kit: Qiagen).
- the sense and antisense primers are Oligonucleotides corresponding to the nucleotide sequences at positions 1051 to 1078 and 4058 to 4085 in column number 1 were used.
- Oligonucleotides corresponding to the nucleotide sequence at positions 1535 to 1552 of SEQ ID NO: 1 and oligonucleotides corresponding to the complementary strand at positions 2892 to 2912 of SEQ ID NO: 1 were used as primers.
- the PCR reaction was performed under the conditions of thermal denaturation at 95 ° C for 1 minute, annealing at 63 ° C for 1 minute, and extension reaction at 72 ° C for 1 minute for 35 cycles.
- the sense and antisense primers used include an oligonucleotide corresponding to the nucleotide sequence at positions 1534 to 1556 of SEQ ID NO: 1, and an oligonucleotide corresponding to the nucleotide sequence at positions 3284 to 3306 of SEQ ID NO: 1, respectively. Nucleotides were used.
- Electrophoresis was performed on agarose gel (1% Agarose S: manufactured by Futatsu Gene) in a TAE buffer together with the molecular weight (100bp ladder: manufactured by New England Biolabs (NEB)).
- a PCR product of about 1.5 kbp was recovered from the gel and purified using a commercial kit (QIAq'uick Gel Extraction Kit: Qiagen). 50 ng of the obtained PCR product, TA clone vector (pT7BlueT vector: manufactured by Novagen) 25 ng T4 DNA ligase solution (solution I of DNA ligation kit Ver II: manufactured by Takara Shuzo) 31 The mixture was mixed and ligated at 16 ° C for 2 hours.
- the precipitate was washed with 70% ethanol, dried, and dissolved in 50 ⁇ l of sterile distilled water.
- the resulting lmg / mlRNase A (Sigma Co.) was added 0. 5 mu 1 was added, 3 after 1 hour Lee Nkigobe preparative 7 ° C, 20% polyethylene grayed recalled Z2.
- 5M chloride Na Application Benefits ⁇ beam Solution 301 was added and left for 1 hour under ice cooling.
- the resulting solution was centrifuged at I2000rp / n for 10 minutes, and the precipitate was washed with 70% ethanol, dried, and dissolved in 30 ⁇ l of sterile distilled water. .
- Terminator Cycle Sequencing Ready Reaction Kit manufactured by Norkin Enorema Co., Ltd.
- the obtained precipitate is dissolved in a formaldehyde / blue dextran (5: 1) solution 31 and heat-treated at 95 ° C for 2 minutes, using a sequencer (ABI PRISM377 DNA Sequencer: PerkinElmer). To determine the base sequence.
- a sequencer (ABI PRISM377 DNA Sequencer: PerkinElmer).
- the clone obtained by subcloning the PCR product obtained by amplifying the mutated genome had a deletion of the nucleotide sequence at positions 2443 to 2456 of SEQ ID NO: 1.
- LOxPf'u buffer (Stratagene) 2.51, 2.5tnM Deoxynucleotide mixture 2 ⁇ l, 20 M sense, antisense primer to 50 ng of genome DNA 0.25 ⁇ 1, DN II polymerase reagent (Pfu DNA polymerase: manufactured by Stratagene) 1.
- PCR was carried out by adding 25 U and adjusting the total volume to 25 using sterile distilled water. . The PCR reaction was performed at 95 for 1 minute, followed by thermal denaturation at 95 ° C for 1 minute, annealing at 55 ° C for 1 minute, and extension reaction 72. C was performed for 1 minute at 40 cycles.
- Primers were used as sense and antisense primers, respectively, oligonucleotides corresponding to the nucleotide sequence at positions 2369 to 2389 of SEQ ID NO: 1. Oligonucleotide corresponding to the nucleotide sequence at positions 2514 to 2535 of SEQ ID NO: 1 was used.
- the amplified PCR product was electrophoresed in TAE buffer on agarose gel (3% GTG Agarose: Takara Shuzo) together with a molecular weight marker (100bp ladder: manufactured by New England Biolabs (NEB)), and the mixture was mixed with a DNA buffer. And visualized with a solution.
- Figure 2 shows the results.
- Example 4 Detection of Splicing Abnormality due to Five Mutations of SEQ ID NO: 1
- 50 ⁇ g of RA or healthy human genomic DNA was added to lOxLA buffer (trade name: Takara Shuzo) 2.5 ⁇ m, 25 mM magnesium chloride 2 ⁇ m 5 ⁇ l, 2.5 mM deoxynucleotide mixture 4 ⁇ l, 20 ⁇ sense, antisense primer 0.25 ⁇ l each, DNA polymerase reagent (LA Taq DNA polymerase: Takara Shuzo) 1.25 U And add 25 ⁇ l with sterile distilled water.
- lOxLA buffer trade name: Takara Shuzo
- DNA polymerase reagent LA Taq DNA polymerase: Takara Shuzo
- PCR reaction was performed. The PCR reaction was performed at 95 ° C for 1 minute, followed by 35 cycles of heat denaturation at 95 ° C for 1 minute, annealing at 63 ° C for 1 minute, and extension reaction at 72 ° C for 2 minutes.
- the primers used for this reaction are shown below.
- Antisense primer A
- the amplified 'PCR product was purified by ethanol precipitation.
- 10 units of Kpn I (Takara Shuzo) and 3 ⁇ l of 10 ⁇ L buffer (Takara Shuzo) were added, and the total volume was made up to 30 l with sterile distilled water.
- 10 units of Xho I (Takara Shuzo) and 4 ⁇ l of ⁇ buffer (Takara Shuzo) make the total volume to 40 ⁇ l with sterile distilled water, and further add 37 ° C For 4 hours.
- This reaction solution was electrophoresed together with a molecular weight marker (lkbp ladder: manufactured by Fermentas) on agarose gel (1% Agarose S: manufactured by Futatsu Gene) in a TAE buffer.
- a molecular weight marker (lkbp ladder: manufactured by Fermentas) on agarose gel (1% Agarose S: manufactured by Futatsu Gene) in a TAE buffer.
- the obtained approximately 1.8 kbp PCR product was recovered from Genoretiki and purified using a commercial kit (QIAquick Gel Extraction Kit: manufactured by QIAGEN). '
- This reaction solution was electrophoresed together with a molecular weight marker (lkbp ladder: manufactured by Fermentas) on an agarose gel (1% Agarose S: manufactured by Futaba Gene) in a TAE buffer.
- a molecular weight marker (lkbp ladder: manufactured by Fermentas) on an agarose gel (1% Agarose S: manufactured by Futaba Gene) in a TAE buffer.
- a 5.6 kbp DNA band was recovered from the gel and purified using a commercially available kit (QIAquick Gel Extraction Kit: Qiagen). '
- the sequence reaction of the plasmid DNA was carried out using a commercially available kit (BigDye Terminator Cycle Sequencing Ready Reaction Kit: manufactured by Norn Enorema Co., Ltd.) by the die terminator method.
- the resulting solution was centrifuged for 20 minutes at 15000rpm and precipitate was washed with 70% ethanol 125 / il, the dried c resulting precipitate formaldehyde Donoburu one dextrin preparative run-. (5: 1) 3 M 1 And heat-treated at 95 ° C for 2 minutes.
- nucleotide sequence was determined using Sequencer-1 (ABI PRISM377 DNA Sequencer: PerkinElmer), substitution of the nucleotide at position ⁇ 55 of SEQ ID NO: 1 from A to G, and positions 2443 to 2456 of SEQ ID NO: 1 Base substitution, substitution of base C at position 2531 in SEQ ID NO: 1 with substitution of base A at position 2678 of SEQ ID NO: 1 with base, substitution of base A at position 2826 with SEQ ID NO: 1 from G to G Mutant vectors having the following substitutions and normal vectors having no mutation were constructed (see Fig. 1).
- the obtained cells were collected, washed with a phosphate buffered saline, and then subjected to total guanidine thiocyanate phenol-clonal form (AGPC) method using Trizol reagent (trade name: Gibco).
- AGPC total guanidine thiocyanate phenol-clonal form
- the c total RNA from which the RNA was prepared was further treated with DNase (manufactured by Nippon Gene Co., Ltd.), and 1 ⁇ of the obtained total RNA was subjected to a reverse transcription reaction kit (RNA PCR Kit: PerkinElmer Inc.). CDNA) was prepared by the usual reverse transcription reaction.
- LOxPCR the resulting c DNA solution 5 mu 1 II buffer (Perkin Elmer Ltd. one company) 2 ⁇ 1, 25raM magnesium 1 mu 1 chloride, 20 Micromax sense, antisense primer, respectively 0. 25 / il, D 'NA Polymerase reagent (Ampli Taq Cold DNA polymerase: manufactured by Norkin Elma Co., Ltd.) 1.
- a PCR reaction was performed using 25 U 'of calorie, and the total amount was adjusted to 25 ⁇ l with sterile distilled water. PCR reactions are 9 after at 5 ° C 10 min, 1 minute denaturation 95 ° C, 1 minute at Aniri ring 55 ° C, 40 cycles of 1 minute extension reaction 72 ° C, finally 72 ° C For 5 minutes.
- the sense and antisense primers used in this reaction are as follows.
- Sense primer B 5'-ATCCGCTTCCTGCCCC-3 '(SEQ ID NO: 8)
- Antisense primer B 5'-GGGGCCACCTCCAGTGCC-3 '
- Each nucleotide sequence is an oligonucleotide corresponding to a part of the nucleotide sequence of the sense primer A and the antisense primer '1A.
- RT-PCR solution was electrophoresed on agarose gel (2% Agarose S: Nippon Gene) in a TAE buffer along with a molecular weight marker (1 kbp ladder: manufactured by Pheno Rementas). Visualized with ethidium bromide solution.
- the PCR product was cut out from the gel and purified using a commercially available kit (QIAquick Gel Extraction Kit: Qiagen).
- the resulting PCR product 50 ng, TA click low Jung vector (P T7BlueT vectored one: Nova one Jen (Novagen) Co.) 25 ng of T4DNA ligase solution (DNA ligation kit Ver II of solution I: manufactured by Takara Shuzo Co., Ltd.) 3 mu 1 And ligated at 16 ° C for 2 hours. . ' ⁇
- Plasmid DNA was prepared in the same manner as in Example 2, and the nucleotide sequence was determined.
- primers oligonucleotides represented by sense primer B and antisense primer B were used.
- -As a result 'The nucleotide sequence at position 1755 of SEQ ID NO: 1 changes from A to G, the nucleotide sequence at positions 2443 to 2456 of SEQ ID NO: 1 is deleted, and the nucleotide sequence at position 2531 of SEQ ID NO: 1 changes from J to T
- the mutation at position 2678 in SEQ ID NO: 1 has a mutation from A to T, and the nucleotide sequence at position 2826 in SEQ ID NO: 1 has a mutation from A to G.
- Positions 2636 to 2792 of SEQ ID NO: 1 were retained: mRNA was detected.
- the DNA in the gel was transferred to a nylon membrane (Hybond-N +: manufactured by Amersham Armacia) by the capillaries method and transferred to a UV loss linker (B: Genetic). More DNA was immobilized on the membrane. LOxSSC was used as a buffer solution for cabillaries. The detection of hybridization and DNA fragments was carried out using a Gene Images 3 'mono-oligobelling' CDP-Star detection system (Amersham Pharmacia) as follows. The DNA-immobilized membrane was mixed with hybridization buffer (5 X SS (: 0.1% (w / v) SDS,
- the oligonucleotide containing the salt' group at positions 2715 to 2736 of SEQ ID NO: 1 is fluoresced. It was labeled and used as a probe. This probe was added to the prehybridization solution so that the probe concentration became lOng / tnl, and hybridization was performed at 59 ° C for 2 hours with further shaking. Wash twice with a buffer solution (5xSSC, 0.1% (w / v) SDS) for 5 minutes, and then wash twice with a buffer solution (lxSSC, 0.1% (w / v) SDS) previously heated to 50 ° C for 15 minutes.
- 5xSSC 0.1% (w / v) SDS
- the membrane was lightly rinsed with buffer A, and the kit was diluted 1:10 with buffer "A” and the kit was blocked with the blocking reagent for 1 hour at room temperature.
- the membrane was lightly rinsed with buffer A.
- Antibody dilution solution Alkaline phosphatase labeled anti-fluorescein supplied with the kit
- Antibody was diluted 5000 times with buffer A containing 0.5% (w / v) BSA) and incubated for 1 hour at room temperature. Washing was performed three times with buffer solution A containing 0.3% (v / v) Tween20 for 10 minutes while shaking at room temperature.
- a mutation from A to G in the nucleotide sequence of 1755 a mutation from C to T in the nucleotide sequence at position 2531 in SEQ ID NO: 1, a mutation from A to T in the nucleotide sequence at position 2678 in SEQ ID NO: 1, SEQ ID NO: 1
- a mutation from A to G in the nucleotide sequence at position 2826 was prepared using a commercially available kit (QuikChangeTM Site-Directed Mutagenesis kit: manufactured by Stofane (Stratagene)) in the following manner.
- Sense primer 5'-GGTTCCCGCAGAGGTACTGACTGTGGGA-3 '(SEQ ID NO: 10)
- Antisense primer 5'-TCCCACAGTCAGTACCTCTGCGGGAACC-3 '(Torumi column number 11).
- Sense primer 5 '-CTTGGCTCACTATAACCTCTGCTGCCTGGG-3' (SEQ ID NO: 12) '
- Antisense primer 5'-CCCAGGCAGCAGAGGTTATAGTGAGCCAAG-3 '(SEQ ID NO: 3 )'
- Anti-antisense primer
- Antisense primer 5'-CAGGGATTTTGCCTATTCTGTCCCCTGTTGC-3 '(SEQ ID NO: 17)
- Example 4 (3) The mutant vector prepared in the same manner as in Example 4 (6) was transfected into Jurkat cells, and RT-PCR was performed under the same conditions as in Example 4 (6). Was done. Further, Southern plotting was performed in the same manner as in the method shown in Example 5. Fig. 4 shows the results. Only in the vector in which the A to T mutation was introduced at position 2678 of SEQ ID NO: 1, a band binding to the probe was detected, and it was revealed that this mutation causes splice aberration.
- RA pedigree 6 out of 60 RA patients and 4 out of 31 healthy RA-affected patients in a group of patients who had RA affected relatives other than the patient themselves (hereinafter referred to as RA pedigree) Mutations were observed in 11 out of 494 RA patients and 3 out of 481 normal healthy subjects in a group of patients without relatives who had no RA, and mutations were found to be extremely high in RA families. Most of the observed mutations were heterozygotes.
- PCR reaction was performed at 95 ° C for 10 minutes, followed by a thermal denaturation reaction at 95 ° C for 1 minute, an annealing reaction at 60 ° C for 1 minute, an extension reaction at 72 ° C for 2 minutes, and finally an extension reaction. This was performed at 72 ° C for 5 minutes.
- the obtained PCR product was purified by multi-screen PCR (trade name: manufactured by Millipore) using an automatic dispensing robot (Biomec 2000: manufactured by Beckman Coulter).
- oligonucleotides corresponding to the nucleotide sequences at positions 2138 and 1517 1535 of SEQ ID NO: 1, respectively were used. .
- PCR product (Terminator Ready Reaction Mix: PerkinElmer) 4 / il, add 1.6 pmol of primer, and add sterile distilled water
- the volume was made up to 10 l. Sequence reaction, 96. C for 10 seconds, 50 ° C for 5 seconds, 60 ° C for 4 minutes, 25 cycles.
- the unreacted deoxynucleotide is removed from the sample after the sequence reaction using Sephadex G-50 (manufactured by Amersham Pharmacia) and Manoletis Clean-HV (product name: manufactured by Millipore). The gel filtration method was used.
- the base at position 921 is based on the base at the 5 'end of exon 3 of the sequence (accession number NM-003790) registered in the gene bank as cDNA, and is one base before the base. If the base number of the lon is -1st, it corresponds to the .53rd.
- Genomic mutations were examined in RA patients in the same manner as in Examples (1) to (3).
- RNA PCR Kit manufactured by Perkin-Dulmer
- the extension reaction was performed under the conditions of 40 cycles of 1 minute at 55 ° C and 2 minutes of extension at 72 ° C, and finally 5 minutes at 72 ° C.
- the sense and antisense primers used in this reaction are as follows.
- the obtained RT-PCR solution was electrophoresed in TAE buffer with 1% Agarose S (Nippon Gene) together with a molecular weight marker (100 bp ladder: Fermentas) in a TAE buffer solution. Visualized by 'Mide solution'.
- the PCR product was cut out of the gel and purified using a commercially available kit (QIAquick Gel Extraction Kit: Qiagen). 50 ng of the obtained PCR product and 25 ng of a TA cloning vector (pT7BlueT vector 1: Novagen) were mixed with 3 ⁇ l of T4 DNA ligase solution (solution I of DNA ligation kit Ver II: Takara Shuzo). The ligation was performed at 16 ° C for 2 hours.
- Example 2 [Plasmid DNA was prepared in the same manner as in the method described here, the nucleotide sequence was determined, and cDN'A at positions 21 to 1342 of SEQ ID NO: 2 or position 21 of SEQ ID NO: 4 A plasmid in which ⁇ 731 cDNA was cloned was obtained.
- the D ⁇ . ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ ⁇ was recovered from the gel force and purified using a commercially available quint (QIAquick Gel Extraction Kit: Qiagen).
- (6) 2 units of pcDNA3.1 / His vector (trade name: manufactured by Invitrogen) contain 5 units of BamH I (manufactured by Takara Shuzo), 5 units of Xba I (manufactured by Takara Shuzo), and ⁇ buffer solution (manufactured by Takara Shuzo) 1.25 / JI was added, and the total volume was adjusted to 25 l with sterile distilled water.
- Plasmid 2 ⁇ in which positions 21 to 1342 of SEQ ID NO: 2 obtained in Reference Example 1 (4) were cloned was also Sal I (Takara Shuzo) 5 units, EcoR I (Takara Shuzo) 5 units, ⁇ 2.5 1 buffer solution (Takara Shuzo) was added, and the total volume was adjusted to 25 with sterile distilled water. After incubating the reaction solution at 37 ° C for 4 hours, agarose gel (1%) was added together with a molecular weight marker (lkbp ladder: manufactured by Fermentas).
- Plasmid DNA was prepared in the same manner as described in Example 2, and an EGFP (Enhanced green fluorescent protein) -tagged expression vector in which L342 was recombined with position 21 to Was built.
- EGFP Enhanced green fluorescent protein
- A-knowledge was collected from Genoreka and purified using a commercial kit (QIAquick Gel Extraction Kit: Agen).
- Plasmid DNA was prepared in the same manner as in Example 2, and an EGFP-tagged expression vector in which positions 21 to 731 of SEQ ID NO: 4 were recombined was constructed.
- Example 6 Reference Example 1 was made in the same manner as in (1) and (2).
- Mutagenesis was performed on the plasmid cloned from the cDNA at positions 21 to 1342 of SEQ ID NO: 2 or the cDNA at positions 21 to 731 of SEQ ID NO: 4 obtained in (4).
- Each of the mutation-introduced salts was the 564th base of SEQ ID NO. 4 or 2 (corresponding to position 1755 of SEQ ID NO: 1), and this base A was replaced with G.
- G By this mutagenesis, Gly replaces Asp at position 159 in all proteins.
- the primer sets used at this time are as follows.
- Antisense primer 5'—TCCCACAGTCAGTACCTCTGCGGGAACA—3 '
- the obtained sample (20 ⁇ ) was subjected to ordinary SDS-PAGE using a 7.53 ⁇ 4 SDS-PAGE gel together with a protein marker (Brested Marker, Broad: manufactured by Apro Science). After electrophoresis, proteins were transferred to a PVDF membrane (Millipore) using a semi-dry blotting device.
- the transfer buffer used was 100 mM Tris, 192 mM glycine, and 10% methanol.
- Fig. 5 shows the results. It was found that proteins expressed from vectors B, C, D, and E all bind to proteins expressed from vector A. That is, the normal DR3 protein forms a complex with the normal protein, and also forms a complex with the mutant proteins expressed from vectors c , D, and E. It became clear that we would do it.
- cDNA solution Human testis Marathon-Ready cDNA: trade name, manufactured by Klontec
- lOxLA buffer trade name: manufactured by Takara Shuzo
- S ⁇ 1 2.5 ⁇ M deoxynucleotide mixture 4 ⁇ l
- Antisense primer 5'-GGTTCAGCAATAGCCGCAGA-3 '(system number 21).
- Plasmid DNA was prepared in the same manner as in the method described in Example 2, the nucleotide sequence was determined, and a plasmid in which TRADD cDNA was cloned was obtained.
- P CMV-Tag2 vector data one (trade name: be sampled La data Gene Co., Ltd.) I ⁇ g to EcoR I (manufactured by Takara Shuzo Co., Ltd.) 5unit, Sal I (manufactured by Takara Shuzo Co., Ltd.) 5unit, ⁇ buffer (Takara Shuzo Co., Ltd. 3 / i 1 was added, and the total amount was adjusted to 30 ⁇ l with sterile distilled water.
- Reference Example 2 30 ng of the DNA fragment purified in (4) and 30 ng of the pCMV-Tag2 vector purified in Reference Example 2 (5) were combined with a T4 DNA ligase solution (solution I of DNA ligation kit Ver II: Takara Shuzo) 2 5 ⁇ l and ligated at 16 ° C for 2 hours.
- a T4 DNA ligase solution solution I of DNA ligation kit Ver II: Takara Shuzo
- vector F a TRADD expression vector with a Flag tag was constructed.
- this vector is referred to as vector F.
- Vector A 0.2 / g, Vector E 0.2 ig, Vector F 0.lfg Vectors A and E are shown in Reference Example 1.
- Vector A has a His tag in addition to an Xpress tag.
- the total amount of the vector was determined to be lg by pcDNA3.1 (trade name: manufactured by Invitrogen). 6 / i1 of a lipofection reagent (plus reagent: Gibco) was added to 1-4 above, and the whole amount was ⁇ with DMEM, and the mixture was allowed to stand at room temperature for 15 minutes.
- Libofectamine reagent manufactured by Gibco 41 and DMEM961 were added, and after standing at room temperature for 15 minutes, 800 ⁇ l of DMEM was added to make the total volume 1 ml. Cells The supernatant was removed from the plates seeded, the solution e total amount of pressure to, for 3 hours at the 37 ° C, 5% C0 2 conditions. After removing the supernatant, 3 ml of DMEM / 10% FCS was added, and after further culturing for 24 hours, the cells were collected. After resulting cells washed with PBS, suspended in solubilization buffer 2 5 0 1, was crushed Le Ri by the ultrasound. The cell lysate of this l 5 000 rpm, centrifuged 10 min, the supernatant was subjected to experiments with a cell lysate.
- washing the supernatant was 20 minutes overturning stirred at 4 ° C and suspended in solubilization buffer 500 1. After performing this operation twice, the same washing was further performed twice with 500 ⁇ l of the washing buffer, and finally, the washing was performed again with the solubilizing buffer 500 / ⁇ 1.
- the precipitate was suspended in 2 ⁇ sample buffer 301 and heated at 95 ° C for 5 minutes to prepare a sample for SDS-polyacrylamide gel electrophoresis (PAGE). (10)
- the obtained sample 201 was subjected to ordinary SDS-PAGE using a 9% SDS-PAGE gel together with a protein marker (pressed marker, broad: manufactured by Aproscience). After electrophoresis, the proteins were transferred to a PVDF membrane using a semi-dry plotting device.
- the transfer buffer used was lOOtnM Tris, 192 mM glycine, and 10% methanol.
- the protein-transferred PVDF membrane was immersed in a 5% skim milk powder-containing TBS solution and shaken at room temperature for 1 hour. Next, the TBS solution was immersed in a solution in which an anti-Flag antibody (manufactured by Sigma) was added at a ratio of 1/1000 (volume ratio to the solvent), and reacted at room temperature for 30 minutes. After washing the PVDF membrane three times for 1 to 2 minutes with TBS solution, immerse in TBS solution containing HRP-labeled anti-mouse IgG antibody (manufactured by Amershamfa / Remashia) in 1/1000 (volume ratio to solvent). The reaction was performed at room temperature for 30 minutes. After washing with a TBS solution three times for 15 minutes, the plate was immersed in a detection reagent (ECL system: manufactured by Amersham Fanolemasia) and exposed to an X-ray film.
- ECL system manufactured by Amersham Fanolemasia
- Fig. 6 shows the results. Normal type DR3 and mutant DR3, when the simultaneous expression, the amount of TRADD bound to dose-dependent manner normal type DR3 variant DR 3 is reduced (Lane 3 ', 4). That is, mutant DR3 inhibited the binding between normal DR3 and TRADD.
- Peripheral blood l Ornl from 5 RA patients and 4 healthy subjects from which heparin was collected was mixed with an equal volume of PBS, and this was overlaid with 20 ml of Lymphoprep (Daiichi Pure Chemicals). l 5 After centrifugation for 30 minutes at rpm, the layer of peripheral blood mononuclear cells were collected and washed in PBS.
- Cells 5x l (J s ce 11 s / ml and by bovine suspended becomes medium (RPM1 16 4 0/10% FCS) were plated the cell suspension 10ml to 10 cm phi dish, PMA (Shi Damasha) With or without stimulation at 20 ng / ml and PHA (Difco) 1 g / ml Under stimulation, 37 ° C, ' 5D /. C0 2 in the cells were cultured for 48 hours. 'The cells were collected, washed with PBS, suspended in 150 ⁇ l of lysis buffer, and incubated for 30 minutes under ice-cooling. This solution was centrifuged at 5000 rpm for 10 minutes, and the supernatant was separated and used as a cell lysate.
- the protein-transferred PVDF membrane was immersed in a 5% skim milk-containing TBS-T solution and shaken at room temperature for 1 hour. Then, the plate was immersed in a solution of anti-caspase-8 antibody (manufactured by Medical Biology Laboratories) at a ratio of 1 / 1,000 (volume ratio to the solvent) added to a 1% skim milk powder-containing TBS-T solution, and the solution was incubated at 4 ° C —Reacted.
- anti-caspase-8 antibody manufactured by Medical Biology Laboratories
- band concentrations of caspase 8 / a and caspase 8 / b were quantified using NIH Image software, and the results were shown as relative values obtained by dividing the values under stimulation with PMA and PHA by the values under non-stimulation. The results are shown below as the average soil standard deviation.
- RA patients 1.33 + 0, 23 Caspase 8 (caspase 8 / a, caspase 8 / b) is reduced or degraded in healthy subjects by cell stimulation, whereas degradation of caspase 8 is observed in RA patients. was not observed.
- Agarose S electrophoresed in TAE buffer using Nippongen ⁇ ..
- a DNA band of about 1.3 kbp was recovered from gel; ⁇ , and commercially available kit (QIAquick Gel Extraction Kit: Qiagen) And purified.
- Plasmid DNA was prepared in the same manner as in Example 2, and a normal DR3 expression vector in which positions 21 to i342 of SEQ ID NO: 2 were recombined was constructed.
- Plasmid DNA was prepared in the same manner as described in Example 2, and a plasmid having a mutation from A to G at position 564 of SEQ ID NO: 3 was prepared. A mutant expression vector in which 73731 was recombined was constructed.
- Cells were harvested Li After washing with phosphate buffered saline, the cells were solubilized in 100 ⁇ l of cell lysate (Passive Lysis Buffer: manufactured by Promega) and 20 ⁇ l of this solution and luciferase substrate 50 (Stop & Glo substrate: Promega) Were mixed, and the luminescence was measured using a Luminometer (Luminoskan: manufactured by Dainippon Pharmaceutical Co., Ltd.).
- the cell lysate emits chemiluminescence.
- the amount of luminescence is considered to decrease due to a decrease in the number of cells. That is, this test detects the induction of cell death using the amount of luminescence as an index.
- the luminescence of cells into which the mutant DR3 was introduced was almost the same as that of the control. showed that. That is, while apoptosis is not induced in these cells, the amount of luminescence of cells into which normal DR3 and mutant DR3 are introduced in equal amounts is equal to that of cells into which only normal DR3 has been introduced. Similarly, it showed a low value, and cell death was induced. Thus, complementation of normal DR3 is considered to be useful as a treatment for RA.
- the present invention relates to a method for diagnosing human rheumatoid arthritis using mutations in the genome or protein having the mutation (in other words, a method for determining the onset or possibility of onset), and a diagnosis (determination) for detecting the mutation.
- the present invention relates to a kit, a method for treating rheumatism and a therapeutic drug. According to the present invention, the onset or possibility of the onset of rheumatoid arthritis can be performed easily and reliably with high accuracy, and is useful. Furthermore, the present invention is also useful as a new method for preventing, treating and treating rheumatoid arthritis.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020037005669A KR100944022B1 (ko) | 2000-10-24 | 2001-10-24 | 만성 관절 류머티즘에 관여하는 게놈, 그 진단방법, 그발증 가능성의 판정방법, 이들의 검출용 진단키트 및 만성관절 류머티즘의 치료방법 및 치료약제 |
JP2002537882A JP3898126B2 (ja) | 2000-10-24 | 2001-10-24 | 慢性関節リウマチに関与するゲノム、その診断方法、その発症可能性の判定方法、それらの検出用診断キットおよび、慢性関節リウマチの治療方法ならびに治療薬剤 |
US10/415,247 US7306908B2 (en) | 2000-10-24 | 2001-10-24 | Nucleic acids associated with rheumatoid arthritis, and methods and kits for the diagnosis thereof |
CA2426765A CA2426765C (en) | 2000-10-24 | 2001-10-24 | Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis |
AU2002210926A AU2002210926B2 (en) | 2000-10-24 | 2001-10-24 | Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis |
EP01978865A EP1335021A4 (en) | 2000-10-24 | 2001-10-24 | GENOMS INVOLVED IN RHEUMATOID ARTHRITIS, METHOD FOR DIAGNOSIS THEREOF, METHOD FOR EVALUATING THE POSSIBILITY OF AN OUTBREAK THEREOF, DIAGNOSTIC KIT FOR DETECTING THESE GENES, THERAPEUTIC METHOD AND MEDICINE FOR ARTHRUME |
AU1092602A AU1092602A (en) | 2000-10-24 | 2001-10-24 | Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detectingthem and therapeutic method and remedies for rheumatoid arthritis |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-324296 | 2000-10-24 | ||
JP2000324296 | 2000-10-24 | ||
JP2001-90546 | 2001-03-27 | ||
JP2001090546 | 2001-03-27 | ||
JP2001-99990 | 2001-03-30 | ||
JP2001099990 | 2001-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002034912A1 true WO2002034912A1 (fr) | 2002-05-02 |
Family
ID=27345019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/009313 WO2002034912A1 (fr) | 2000-10-24 | 2001-10-24 | Genomes participant a l'arthrite rhumatoide, procede de diagnostic de celle-ci, procede d'evaluation de la possibilite d'apparition de celle-ci, kit de diagnostic et methode et remedes therapeutiques destines a l'ar |
Country Status (7)
Country | Link |
---|---|
US (1) | US7306908B2 (ja) |
EP (1) | EP1335021A4 (ja) |
JP (1) | JP3898126B2 (ja) |
KR (1) | KR100944022B1 (ja) |
AU (2) | AU2002210926B2 (ja) |
CA (1) | CA2426765C (ja) |
WO (1) | WO2002034912A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005083071A1 (ja) * | 2004-02-26 | 2005-09-09 | Shunichi Shiozawa | 関節リウマチの発症に関与するポリヌクレオチドおよびその利用 |
JP2006067829A (ja) * | 2004-08-31 | 2006-03-16 | Institute For Rheumatic Diseases Co Ltd | DR3遺伝子のd領域に結合するポリペプチドおよびその利用 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4242590B2 (ja) | 2002-01-11 | 2009-03-25 | 俊一 塩澤 | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 |
EP2353615B1 (en) * | 2003-08-20 | 2014-11-19 | University of Miami | Compositions and methods for treating inflammatory lung disease |
WO2007027751A2 (en) | 2005-08-30 | 2007-03-08 | University Of Miami | Immunomodulating tumor necrosis factor receptor 25 (tnfr25) agonists, antagonists and immunotoxins |
TWI531362B (zh) | 2008-07-21 | 2016-05-01 | 艾爾康股份有限公司 | 具有治療劑遞送能力之眼科裝置 |
WO2010062960A2 (en) | 2008-11-26 | 2010-06-03 | Cedars-Sinai Medical Center | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE |
AU2010279637B2 (en) | 2009-08-03 | 2012-08-23 | University Of Miami | Method for in vivo expansion of T regulatory cells |
US8766034B2 (en) | 2010-09-22 | 2014-07-01 | Cedars-Sinai Medical Center | TL1A model of inflammation fibrosis and autoimmunity |
JP2016504045A (ja) | 2013-01-09 | 2016-02-12 | ザ ユニバーシティー オブ マイアミThe University Of Miami | TL1A−Ig融合タンパク質を用いる制御性T細胞の制御のための組成物及び方法 |
CA2908553A1 (en) | 2013-03-27 | 2014-10-02 | Cedars-Sinai Medical Center | Mitigation and reversal of fibrosis and inflammation by inhibition of tl1a function and related signaling pathways |
WO2015010108A1 (en) | 2013-07-19 | 2015-01-22 | Cedars-Sinai Medical Center | Signature of tl1a (tnfsf15) signaling pathway |
ES2727656T3 (es) | 2014-09-15 | 2019-10-17 | Abvitro Llc | Secuenciación de alto rendimiento de banco de nucleótidos |
KR20180127416A (ko) | 2016-03-17 | 2018-11-28 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
WO2021046343A1 (en) * | 2019-09-06 | 2021-03-11 | Teleflex Medical Incorporated | Lysing solution for real-time determining the identification and antibiotic resistance of pathogenic microorganisms |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033904A1 (en) * | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
WO1998051791A1 (fr) * | 1997-05-15 | 1998-11-19 | Shunichi Shiozawa | Gene responsable de l'arthrite rhumatoide, methode pour diagnostiquer l'arthrite rhumatoide et procede permettant de determiner des facteurs responsables de l'arthrite rhumatoide |
WO2001032921A2 (en) * | 1999-11-01 | 2001-05-10 | Shunichi Shiozawa | Method of diagnosing rheumatoid arthritis |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585464A (en) | 1993-02-19 | 1996-12-17 | Theratech, Inc. | Recombinant antigen for diagnosing rheumatoid arthritis |
CA2158822C (en) | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
DK1164190T3 (da) | 1999-03-20 | 2011-08-15 | Shunichi Shiozawa | Rheumatoid arthrit-gen og fremgangsmåde til diagnose af rheumatoid arthrit |
-
2001
- 2001-10-24 AU AU2002210926A patent/AU2002210926B2/en not_active Expired
- 2001-10-24 EP EP01978865A patent/EP1335021A4/en not_active Ceased
- 2001-10-24 CA CA2426765A patent/CA2426765C/en not_active Expired - Lifetime
- 2001-10-24 KR KR1020037005669A patent/KR100944022B1/ko active IP Right Grant
- 2001-10-24 US US10/415,247 patent/US7306908B2/en not_active Expired - Lifetime
- 2001-10-24 JP JP2002537882A patent/JP3898126B2/ja not_active Expired - Lifetime
- 2001-10-24 AU AU1092602A patent/AU1092602A/xx active Pending
- 2001-10-24 WO PCT/JP2001/009313 patent/WO2002034912A1/ja active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997033904A1 (en) * | 1996-03-12 | 1997-09-18 | Human Genome Sciences, Inc. | Death domain containing receptors |
WO1998051791A1 (fr) * | 1997-05-15 | 1998-11-19 | Shunichi Shiozawa | Gene responsable de l'arthrite rhumatoide, methode pour diagnostiquer l'arthrite rhumatoide et procede permettant de determiner des facteurs responsables de l'arthrite rhumatoide |
WO2001032921A2 (en) * | 1999-11-01 | 2001-05-10 | Shunichi Shiozawa | Method of diagnosing rheumatoid arthritis |
Non-Patent Citations (7)
Title |
---|
KOUICHI MURAYAMA ET AL.: "Mansei kansetsu rheumatism (RA) no shikkan idenshi death receptor 3 (DR3) heni no doutei", RHEUMATISM, vol. 41, no. 2, 17 April 2001 (2001-04-17), pages 509, XP002908512 * |
See also references of EP1335021A4 * |
SHIOZAWA, S. ET A.: "An approach to identify new genes in autoimmune diseases: lessons from rheumatoid arthritis", REV. IMMUNOGENET., vol. 2, no. 1, 25 April 2000 (2000-04-25), pages 133 - 139, XP002908516 * |
SHUNICHI SHIOZAWA ET AL.: "Mansei kansetsu rheumatism (RA) no shikkan idenshi", RHEUMATISM, vol. 41, no. 2, 17 April 2001 (2001-04-17), pages 335, XP002908513 * |
SHUNICHI SHIOZAWA ET AL.: "Mansei kansetsu rheumatism to shikkan idenshi", vol. 41, no. 4, 31 August 2001 (2001-08-31), pages 763 - 772, XP002908515 * |
SHUNICHI SHIOZAWA ET AL.: "Shikkan idenshi kara mita mansei kansetsu rheumatism (RA) no byoutai to chiryou", NIPPON SEIKEI GEKA GAKKAI ZASSHI, vol. 75, no. 2, 25 February 2001 (2001-02-25), pages S15, XP002908511 * |
SHUNICHI SIOZAWA ET AL.: "Mansei kansetsu rheumatism to shikkan idenshi", SAISHIN IGAKU, vol. 56, no. 4, 10 April 2001 (2001-04-10), pages 833 - 844, XP002908514 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005083071A1 (ja) * | 2004-02-26 | 2005-09-09 | Shunichi Shiozawa | 関節リウマチの発症に関与するポリヌクレオチドおよびその利用 |
US7741030B2 (en) | 2004-02-26 | 2010-06-22 | Shunichi Shiozawa | Methods for diagnosing rheumatoid arthritis |
JP2006067829A (ja) * | 2004-08-31 | 2006-03-16 | Institute For Rheumatic Diseases Co Ltd | DR3遺伝子のd領域に結合するポリペプチドおよびその利用 |
Also Published As
Publication number | Publication date |
---|---|
JP3898126B2 (ja) | 2007-03-28 |
JPWO2002034912A1 (ja) | 2004-03-04 |
AU2002210926B2 (en) | 2005-12-15 |
EP1335021A4 (en) | 2004-09-22 |
US20040013655A1 (en) | 2004-01-22 |
KR20030074611A (ko) | 2003-09-19 |
CA2426765C (en) | 2012-06-05 |
CA2426765A1 (en) | 2003-04-03 |
AU1092602A (en) | 2002-05-06 |
EP1335021A1 (en) | 2003-08-13 |
KR100944022B1 (ko) | 2010-02-24 |
US7306908B2 (en) | 2007-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5603145B2 (ja) | 疾患のイメージング、診断、及び治療 | |
US20040191818A1 (en) | Compositions and methods for diagnosing and treating autoimmune diseases | |
WO2002034912A1 (fr) | Genomes participant a l'arthrite rhumatoide, procede de diagnostic de celle-ci, procede d'evaluation de la possibilite d'apparition de celle-ci, kit de diagnostic et methode et remedes therapeutiques destines a l'ar | |
CA2265480C (en) | Mutations in the diabetes susceptibility genes hepatocyte nuclear factor (hnf) 1 alpha (.alpha.), hnf-1.beta. and hnf-4.alpha. | |
JPWO2007123233A1 (ja) | 動脈硬化性疾患関連遺伝子、およびその利用 | |
US20050170500A1 (en) | Methods for identifying risk of melanoma and treatments thereof | |
AU2003248794B2 (en) | Therapeutic methods for reducing fat deposition and treating associated conditions | |
US20050277118A1 (en) | Methods for identifying subjects at risk of melanoma and treatments thereof | |
US20080199480A1 (en) | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | |
JP2000511765A (ja) | 精製SR―p70タンパク質 | |
CA2400638A1 (en) | 7 human ovarian and ovarian cancer associated proteins | |
WO2006022619A2 (en) | Methods for identifying risk of type ii diabetes and treatments thereof | |
US20050130151A1 (en) | Method and identification of downstream mrna ligands to fmrp and their role in fragile x syndrome and associated disorders | |
JP4242590B2 (ja) | 慢性関節リウマチの疾患感受性遺伝子、及びその利用 | |
US8084434B2 (en) | Runx2 isoforms in angiogenesis | |
US6797472B1 (en) | Variation in drug response related to polymorphisms in β2-adrenergic receptor | |
JP2005522519A (ja) | 精神分裂病関連遺伝子 | |
WO2004040301A1 (ja) | 2型糖尿病の診断方法 | |
US20030079236A1 (en) | Polymorphisms associated with internalizing disorders | |
US20040018497A1 (en) | Human obesity LIPIN3 polynucleotide and polypeptide sequences and methods of use thereof | |
JP2006325524A (ja) | 神経幹細胞及び脳神経疾患のためのマーカー | |
US20030165844A1 (en) | Haplotypes of the TNFRSF1A gene | |
CA2418680A1 (en) | 11 human secreted proteins | |
WO2002079466A1 (en) | Genomic dnas participating in rheumatoid arthritis, method of diagnosing the same, method of judging onset riks thereof and diagnostic kit for detecting the same | |
CA2418474A1 (en) | 21 human secreted proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002210926 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002537882 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2426765 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10415247 Country of ref document: US Ref document number: 1020037005669 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001978865 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001978865 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037005669 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002210926 Country of ref document: AU |